New Research and Funding Aim to Improve Brain Cancer Treatments
New federal funding secured by U.S. Representative Debbie Wasserman Schultz is propelling pioneering brain cancer research at Nova Southeastern University. The $1 million investment supports the study of carbon dot treatments for brain tumors, targeting inoperable cancers through advanced noninvasive drug delivery systems.
- Nova Southeastern University received over $1 million in federal funding to advance carbon dot treatment for brain tumors, announced during an April 8 event at the Alan B. Levan | NSU Broward Center of Innovation.
- The research focuses on tiny carbon nanoparticles capable of crossing the blood-brain barrier to deliver targeted chemotherapy directly to tumor cells at lower doses.
- Led by Regina Graham, Ph.D., the project aims to acquire advanced biomedical imaging systems to study cellular-level mechanisms and move the novel therapy toward clinical application.
Brain cancer remains one of the most clinically challenging and fatal conditions in oncology. According to National Institutes of Health data cited by Nova Southeastern University, brain cancer serves as the leading cause of cancer death for children aged 1 to 14, carrying an overall five-year survival rate of 33 percent. Geographic incidence rates also show notable regional variations, with Florida ranking eighth nationally for individuals under 50 diagnosed with brain tumors, and Broward County falling within the top 9 percent statewide for total diagnoses.
To address these stark survival metrics, the newly secured federal funds will enable the acquisition of a highly sensitive imaging system and advanced biomedical equipment. This infrastructure allows researchers under the direction of Regina Graham, Ph.D., associate professor at NSU’s Dr. Kiran C. Patel College of Allopathic Medicine, to study carbon dot interactions at the cellular level.
Carbon dot treatment utilizes nontoxic carbon nanoparticles roughly 100,000 times smaller than the width of a human hair. Preclinical findings indicate that these nanoparticles can successfully cross the blood-brain barrier, a biological obstacle that historically neutralizes many conventional systemic chemotherapies. By enabling targeted delivery directly to tumor sites, the approach permits lower therapeutic doses, which may reduce systemic toxicity and adverse side effects for patients managing aggressive malignancies like glioblastoma.
"With this funding, NSU is expanding the frontiers of brain cancer research and accelerating discoveries that can change lives," stated Harry Moon, M.D., NSU president and chief executive officer, noting that the investment strengthens the institution's commitment to effective clinical interventions.
This academic initiative aligns with broader national efforts early in the year to accelerate neuro-oncology breakthroughs. Concurrently, the National Brain Tumor Society announced multi-million-dollar funding initiatives in 2026 targeting rare pediatric tumors and adult glioblastoma resistance mechanisms through collaborative research networks.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*